Compare Eli Lilly And Co (LLY) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.41 (market cap $72.20B). The key difference: Eli Lilly And Co is far larger — about 14.4× Vanguard Intermediate Term Corporate Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vanguard Intermediate Term Corporate Bond ETF for 62 Days on average.
| LLY | VCIT | |
|---|---|---|
Market Cap | $1.04T | $72.20B |
Volume | 3,064,878 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $1.28K | $84.82 |
52-Week Low | $799.57 | $77.98 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $78.41 with a slight 0.18% daily gain. Technical indicators show a bearish overall signal with moving averages suggesting selling pressure, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent news highlights institutional buying interest and competitive advantages in expense ratios compared to peers.
The outlook for VCIT remains balanced with its 4.8% yield providing income appeal, though technical weakness suggests near-term caution. Key risks include interest rate sensitivity and corporate credit quality. Institutional accumulation and low expense ratios support long-term positioning for income-focused investors in the intermediate corporate bond space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
